keyword
MENU ▼
Read by QxMD icon Read
search

Xofigo

keyword
https://www.readbyqxmd.com/read/28631036/practical-recommendations-for-radium-223-treatment-of-metastatic-castration-resistant-prostate-cancer
#1
Yong Du, Ignasi Carrio, Giuseppe De Vincentis, Stefano Fanti, Harun Ilhan, Caroline Mommsen, Egbert Nitzsche, Francis Sundram, Wouter Vogel, Wim Oyen, Val Lewington
PURPOSE: Radium Ra 223 dichloride (radium-223, Xofigo®) is the first targeted alpha therapy for patients with castration-resistant prostate cancer and symptomatic bone metastases. Radium-223 provides a new treatment option for this setting, but also necessitates a new treatment management approach. We provide straightforward and practical recommendations for European nuclear medicine centres to optimize radium-223 service provision. METHODS: An independent research consultancy agency observed radium-223 procedures and conducted interviews with all key staff members involved in radium-223 treatment delivery in 11 nuclear medicine centres across six countries (Germany, Italy, the Netherlands, Spain, Switzerland and the UK) experienced in administering radium-223...
September 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28567494/therapy-assessment-of-bone-metastatic-disease-in-the-era-of-223-radium
#2
REVIEW
Elba Etchebehere, Ana Emilia Brito, Alireza Rezaee, Werner Langsteger, Mohsen Beheshti
PURPOSE: Defining an optimal imaging modality for assessment of therapy and the best time of evaluation are pivotal for ideal patient's management. METHODS: (223)Ra (Xofigo®, formerly Alpharadin) has been approved by the FDA and European Medicines Agency for treatment of metastatic castration-resistant prostate cancer with painful osseous involvement. RESULTS: PET/CT imaging using various radiotracers such as (18)F-FDG, (18)F-FCH, (68)Ga-PSMA and (18)F-NaF have been investigated to mitigate the limitations of conventional imaging modalities...
August 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28427834/doped-silica-fibre-thermoluminescence-measurements-of-radiation-dose-in-the-use-of-223-ra
#3
Bradley, S F Abdul Sani, A S Siti Shafiqah, S M Collins, R P Hugtenburg, H A Abdul Rashid, Nurul Najua Zulkepely, M J Maah
Using tailor-made sub-mm dimension doped-silica fibres, thermoluminescent dosimetric studies have been performed for α-emitting sources of (223)RaCl2 (the basis of the Bayer Healthcare product Xofigo®). The use of (223)RaCl2 in the palliative treatment of bone metastases resulting from late-stage castration-resistant prostate cancer focuses on its favourable uptake in metabolically active bone metastases. Such treatment benefits from the high linear energy transfer (LET) and associated short path length (<100µm) of the α-particles emitted by (223)Ra and its decay progeny...
April 14, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28364014/radium-223-inhibits-osseous-prostate-cancer-growth-by-dual-targeting-of-cancer-cells-and-bone-microenvironment-in-mouse-models
#4
Mari I Suominen, Katja M Fagerlund, Jukka P Rissanen, Yvonne M Konkol, Jukka P Morko, ZhiQi Peng, Esa J Alhoniemi, Salla K Laine, Eva Corey, Dominik Mumberg, Karl Ziegelbauer, Sanna-Maria Käkönen, Jussi M Halleen, Robert L Vessella, Arne Scholz
Purpose: Radium-223 dichloride (radium-223, Xofigo), a targeted alpha therapy, is currently used for the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastases. This study examines the mode-of-action and antitumor efficacy of radium-223 in two prostate cancer xenograft models.Experimental Design: Mice bearing intratibial LNCaP or LuCaP 58 tumors were randomized into groups (n = 12-17) based on lesion grade and/or serum PSA level and administered radium-223 (300 kBq/kg) or vehicle, twice at 4-week intervals...
August 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28216330/-223-ra-dichloride-spectrometric-characterization-searching-for-the-presence-of-long-lived-isotopes-with-radiological-protection-implications
#5
J Sánchez-Jiménez, A López-Montes, L Núñez-Martínez, A Villa-Abaunza, L M Fraile, V Sánchez-Tembleque, J M Udías
(223)Ra-dichloride was approved with the commercial name of Xofigo in 2014 for treatment of metastatic castration-resistant prostate cancer. (223)Ra is obtained by neutron irradiation of (226)Ra yielding (227)Ac, which decays to (227)Th and (223)Fr, both decaying to (223)Ra. Since (223)Ra is predominantly (95.3%) an alpha emitter with a 11.42days long half-life, the radiopharmaceutical, its remnants, the patient, and waste material can be managed and disposed with low radiation protection requirements. (227)Ac is a long-lived (T1/2=21...
March 2017: Physica Medica: PM
https://www.readbyqxmd.com/read/28058455/-bone-specific-therapy-with-radium-223-dichloride-castration-resistant-prostate-cancer-with-symptomatic-bone-metastases
#6
R Tauber, J Gschwend, K Scheidhauer, M Eiber, M Krönke
Radium-223 dichloride (Xofigo®, Alpharadin) is approved for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastases. As a calcium mimetic, it is integrated into osteoplastic bone lesions and emits alpha particles with high energy which leads to local destruction of tumor cells. In the 2013 published ALSYMPCA trial, a significant advantage for overall survival and quality of life in comparison to placebo was found. Recent data suggest an increased potential in combination with next generation hormonal treatment...
January 2017: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27893426/sublethal-exposure-to-alpha-radiation-223ra-dichloride-enhances-various-carcinomas-sensitivity-to-lysis-by-antigen-specific-cytotoxic-t-lymphocytes-through-calreticulin-mediated-immunogenic-modulation
#7
Anthony S Malamas, Sofia R Gameiro, Karin M Knudson, James W Hodge
Radium-223 dichloride (Xofigo®; 223Ra) is an alpha-emitting radiopharmaceutical FDA-approved for the treatment of bone metastases in patients with advanced castration-resistant prostate cancer. It is also being examined clinically in patients with breast and lung carcinoma and patients with multiple myeloma. As with other forms of radiation, the aim of 223Ra is to reduce tumor burden by directly killing tumor cells. External beam (photon) and proton radiation have been shown to augment tumor sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes (CTLs)...
December 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/27774318/radium-223-therapy-for-patients-with-metastatic-castrate-resistant-prostate-cancer-an-update-on-literature-with-case-presentation
#8
REVIEW
Nghi C Nguyen, Muhammad Shah, Leonard J Appleman, Rahul Parikh, James M Mountz
Background and Purpose. Radium-223 dichloride (Xofigo®, Bayer HealthCare Pharmaceuticals Inc.) is the first α-particle emitter therapeutic agent approved by the FDA, with benefits in overall survival and delay in symptomatic skeletal event for patients with metastatic castrate-resistant prostate cancer (CRPC). Recent post hoc analyses of the phase III ALSYMPCA trial support the previously established safety profile as well as therapeutic effect and clinical outcome of Radium-223. Currently, Radium-223 is approved as a single agent therapy for metastatic CRPC...
2016: International Journal of Molecular Imaging
https://www.readbyqxmd.com/read/27749411/benefit-of-68ga-psma-pet-ct-in-patients-considered-for-223ra-dichloride-therapy
#9
Axel Bode, Kambiz Rahbar, Julia Konnert, Martin Bögemann, Lars Stegger
A 66-year-old man with castration-resistant prostate carcinoma and multiple symptomatic bone mestastases was considered for Ra-dichloride (Xofigo) therapy. Staging with Ga-PSMA-PET/CT revealed additional extensive tumor involvement of the spine without relevant uptake in bone scintigraphy. Based on this imaging result, the patient was rescheduled for a PSMA-targeted therapy. Additional Ga-PSMA-PET/CT may have a considerable benefit for patients considered for Xofigo.
December 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27535972/in-vitro-and-in-vivo-efficacy-of-a-novel-cd33-targeted-thorium-227-conjugate-for-the-treatment-of-acute-myeloid-leukemia
#10
Urs B Hagemann, Katrine Wickstroem, Ellen Wang, Adam O Shea, Kristine Sponheim, Jenny Karlsson, Roger M Bjerke, Olav B Ryan, Alan S Cuthbertson
The clinical efficacy of the first approved alpha pharmaceutical, Xofigo (radium-223 dichloride, (223)RaCl2), has stimulated significant interest in the development of new alpha-particle emitting drugs in oncology. Unlike radium-223 ((223)Ra), the parent radionuclide thorium-227 ((227)Th) is able to form highly stable chelator complexes and is therefore amenable to targeted radioimmunotherapy. We describe the preparation and use of a CD33-targeted thorium-227 conjugate (CD33-TTC), which binds to the sialic acid receptor CD33 for the treatment of acute myeloid leukemia (AML)...
October 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27347625/dosing-administration-and-safety-of-radium-223-how-i-do-it
#11
Tu D Dan, Laura Doyle, Amar J Raval, Andrew Pridjian, Leonard G Gomella, Robert B Den
Radium-223 dichloride is a first-in-class bone-directed radiopharmaceutical that has been shown to prolong survival in men with metastatic castrate resistant prostate cancer (mCRPC). Unlike other radiopharmaceuticals, radium-223 uniquely uses alpha-emission to deliver high intensity, short range cytoxic treatments resulting in minimal myelosuppression. Following the results of the ALSYMPCA trial, radium-223 (Xofigo) was FDA approved in the United States in May 2013 and approved by Health Canada in December 2013 for the treatment of mCRPC with symptomatic bone metastases and no visceral disease...
June 2016: Canadian Journal of Urology
https://www.readbyqxmd.com/read/27090254/32nd-international-austrian-winter-symposium-zell-am-see-the-netherlands-20-23-january-2016
#12
W Langsteger, A Rezaee, W Loidl, H S Geinitz, F Fitz, M Steinmair, G Broinger, L Pallwien-Prettner, M Beheshti, L Imamovic, M Beheshti, G Rendl, D Hackl, O Tsybrovsky, M Steinmair, K Emmanuel, F Moinfar, C Pirich, W Langsteger, A Bytyqi, G Karanikas, M Mayerhöfer, O Koperek, B Niederle, M Hartenbach, T Beyer, K Herrmann, J Czernin, I Rausch, P Rust, M D DiFranco, M Lassen, A Stadlbauer, M E Mayerhöfer, M Hartenbach, M Hacker, T Beyer, K Binzel, R Magnussen, W Wei, M U Knopp, D C Flanigan, C Kaeding, M V Knopp, A Leisser, M Nejabat, M Hartenbach, G Kramer, M Krainer, M Hacker, A Haug, Wencke Lehnert, Karl Schmidt, Sharok Kimiaei, Marcus Bronzel, Andreas Kluge, C L Wright, K Binzel, J Zhang, Evan Wuthrick, Piotr Maniawski, M V Knopp, M Blaickner, E Rados, A Huber, M Dulovits, H Kulkarni, S Wiessalla, C Schuchardt, R P Baum, B Knäusl, D Georg, M Bauer, B Wulkersdorfer, W Wadsak, C Philippe, H Haslacher, M Zeitlinger, O Langer, M Bauer, M Feldmann, R Karch, W Wadsak, M Zeitlinger, M J Koepp, M-C Asselin, E Pataraia, O Langer, M Zeilinger, C Philippe, M Dumanic, F Pichler, J Pilz, M Hacker, W Wadsak, M Mitterhauser, L Nics, B Steiner, M Hacker, M Mitterhauser, W Wadsak, A Traxl, Thomas Wanek, Kushtrim Kryeziu, Severin Mairinger, Johann Stanek, Walter Berger, Claudia Kuntner, Oliver Langer, S Mairinger, T Wanek, A Traxl, M Krohn, J Stanek, T Filip, M Sauberer, C Kuntner, J Pahnke, O Langer, D Svatunek, C Denk, M Wilkovitsch, T Wanek, T Filip, C Kuntner-Hannes, J Fröhlich, H Mikula, C Denk, D Svatunek, T Wanek, S Mairinger, J Stanek, T Filip, J Fröhlich, H Mikula, C Kuntner-Hannes, T Balber, J Singer, J Fazekas, C Rami-Mark, N Berroterán-Infante, E Jensen-Jarolim, W Wadsak, M Hacker, H Viernstein, M Mitterhauser, C Denk, D Svatunek, B Sohr, H Mikula, J Fröhlich, T Wanek, C Kuntner-Hannes, T Filip, S Pfaff, C Philippe, M Mitterhauser, M Hartenbach, M Hacker, W Wadsak, T Wanek, E Halilbasic, M Visentin, S Mairinger, B Stieger, C Kuntner, M Trauner, O Langer, P Lam, M Aistleitner, R Eichinger, C Artner, H Eidherr, C Vraka, A Haug, M Mitterhauser, L Nics, M Hartenbach, M Hacker, W Wadsak, H Kvaternik, R Müller, D Hausberger, C Zink, R M Aigner, U Cossío, M Asensio, A Montes, S Akhtar, Y Te Welscher, R van Nostrum, V Gómez-Vallejo, J Llop, F VandeVyver, T Barclay, N Lippens, M Troch, L Hehenwarter, B Egger, J Holzmannhofer, M Rodrigues-Radischat, C Pirich, N Pötsch, I Rausch, D Wilhelm, M Weber, J Furtner, G Karanikas, A Wöhrer, M Mitterhauser, M Hacker, T Traub-Weidinger, T Cassou-Mounat, S Balogova, V Nataf, M Calzada, V Huchet, K Kerrou, J-Y Devaux, M Mohty, L Garderet, J-N Talbot, S Stanzel, G Pregartner, T Schwarz, V Bjelic-Radisic, B Liegl-Atzwanger, R Aigner, S Stanzel, F Quehenberger, R M Aigner, A Koljević Marković, Milica Janković, V Miler Jerković, M Paskaš, G Pupić, R Džodić, D Popović, M C Fornito, D Familiari, P Koranda, H Polzerová, I Metelková, L Henzlová, R Formánek, E Buriánková, M Kamínek, W H Thomson, C Lewis, W H Thomson, J O'Brien, G James, A Notghi, H Huber, I Stelzmüller, R Wunn, M Mandl, F Fellner, B Lamprecht, M Gabriel, M C Fornito, G Leonardi, W H Thomson, J O'Brien, G James, J Hudzietzová, J Sabol, M Fülöp
A1 68Ga-PSMA PET/CT in staging and restaging of Prostate Cancer Patients: comparative study with 18F-Choline PET/CTW Langsteger, A Rezaee, W Loidl, HS Geinitz, F Fitz, M Steinmair, G Broinger, L Pallwien-Prettner, M BeheshtiA2 F18 Choline PET - CT: an accurate diagnostic tool for the detection of parathyroid adenoma?L Imamovic, M Beheshti, G Rendl, D Hackl, O Tsybrovsky, M Steinmair, K Emmanuel, F Moinfar, C Pirich, W LangstegerA3 [18F]Fluoro-DOPA-PET/CT in the primary diagnosis of medullary thyroid carcinomaA Bytyqi, G Karanikas, M Mayerhöfer, O Koperek, B Niederle, M HartenbachA4 Variations of clinical PET/MR operations: An international survey on the clinical utilization of PET/MRIT Beyer, K Herrmann, J CzerninA5 Standard Dixon-based attenuation correction in combined PET/MRI: Reproducibility and the possibility of Lean body mass estimationI Rausch, P Rust, MD DiFranco, M Lassen, A Stadlbauer, ME Mayerhöfer, M Hartenbach, M Hacker, T BeyerA6 High resolution digital FDG PET/MRI imaging for assessment of ACL graft viabilityK Binzel, R Magnussen, W Wei, MU Knopp, DC Flanigan, C Kaeding, MV KnoppA7 Using pre-existing hematotoxicity as predictor for severe side effects and number of treatment cycles of Xofigo therapyA Leisser, M Nejabat, M Hartenbach, G Kramer, M Krainer, M Hacker, A HaugA8 QDOSE - comprehensive software solution for internal dose assessmentWencke Lehnert, Karl Schmidt, Sharok Kimiaei, Marcus Bronzel, Andreas KlugeA9 Clinical impact of Time-of-Flight on next-generation digital PET imaging of Yttrium-90 radioactivity following liver radioembolizationCL Wright, K Binzel, J Zhang, Evan Wuthrick, Piotr Maniawski, MV KnoppA10 Snakes in patients! Lessons learned from programming active contours for automated organ segmentationM Blaickner, E Rados, A Huber, M Dulovits, H Kulkarni, S Wiessalla, C Schuchardt, RP Baum, B Knäusl, D GeorgA11 Influence of a genetic polymorphism on brain uptake of the dual ABCB1/ABCG2 substrate [11C]tariquidarM Bauer, B Wulkersdorfer, W Wadsak, C Philippe, H Haslacher, M Zeitlinger, O LangerA12 Outcome prediction of temporal lobe epilepsy surgery from P-glycoprotein activity...
April 2016: EJNMMI Research
https://www.readbyqxmd.com/read/26583636/navigating-treatment-of-metastatic-castration-resistant-prostate-cancer-nursing-perspectives
#13
REVIEW
Frank dela Rama, Caroline Pratz
BACKGROUND: Treatment of metastatic castration-resistant prostate cancer (mCRPC) has evolved rapidly. In particular, five new treatments that extend survival in mCRPC have been approved since 2010, including the chemotherapy cabazitaxel (Jevtana®), hormonal agents abiraterone (Zytiga®) and enzalutamide (Xtandi®), vaccine sipuleucel-T (Provenge®), and radiopharmaceutical radium-223 (Xofigo®); all have different indications and toxicity profiles. OBJECTIVES: This review discusses treatment advances in mCRPC, including considerations for side-effect management and treatment sequencing...
December 2015: Clinical Journal of Oncology Nursing
https://www.readbyqxmd.com/read/26573043/health-economics-and-radium-223-xofigo%C3%A2-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer-mcrpc-a-case-history-and-a-systematic-review-of-the-literature
#14
REVIEW
Jan Norum, Erik R Traasdahl, Arpad Totth, Carsten Nieder, Jan Abel Olsen
OBJECTIVES: Prostate cancer (PC) is the most common cancer in Western countries. Recent advances in the treatment of metastatic castration resistant prostate cancer (mCRPC) have caused significant pressure on health care budgets. We aimed to exemplify this dilemma presenting an example, radium-223 (Xofigo®), and review the literature. METHODS: A 74-year-old man diagnosed with mCRPC was referred to our department in October 2014 for radium-223 therapy. We faced the following dilemma: is radium-223 standard therapy? Is it cost-effective? Medline was searched employing the following search criteria: "radium-223", "alpharadin", "Xofigo" and "prostate"...
July 30, 2015: Global Journal of Health Science
https://www.readbyqxmd.com/read/26532585/health-economics-and-radium-223-xofigo%C3%A2-in-the-treatment-of-metastatic-castration-resistant-prostate-cancer-mcrpc-a-case-history-and-a-systematic-review-of-the-literature-on-cost-effectiveness-analysis-cea
#15
J Norum, E Traasdahl, A Totth, C Nieder, J A Olsen
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26392087/haematopoietic-toxicity-of-radium-223-in-patients-with-high-skeletal-tumour-burden
#16
M Miederer, C Thomas, J Beck, C Hampel, C Krieger, P E Baqué, A Helisch, M Schreckenberger
UNLABELLED: In patients with metastasized, castration resistant prostate cancer (mCRPC) treatment with radium-223 (Xofigo) is an attractive therapeutic option. In particular, patients with high tumour load seem to profit from this treatment in regard of survival and quality of live. Aim of this study was to stratify mCRPC patients according to a quantitative imaging marker derived from routine bone scans (EXINI bone) and analyze haematopoietic toxicity of Xofigo in these patients. PATIENTS, METHODS: Toxicity and oncologic outcome were investigated in a cohort of 14 patients with high tumour load...
2015: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/26359562/palliation-of-extensive-metastatic-bone-disease-with-223ra-dichloride-%C3%AE-particle-therapy-in-a-patient-with-malignant-hereditary-paraganglioma-pheochromocytoma-syndrome-with-sdhb-mutation
#17
William Makis, Karey McCann, Alexander J B McEwan, Michael B Sawyer
A 26-year-old woman with a 5-year history of metastatic paraganglioma due to hereditary paraganglioma-pheochromocytoma syndrome with SDHB mutation, who had failed multiple treatment regimens and had transfusion dependent pancytopenia, presented with progressive liver and bone metastases. She was unable to sleep due to painful skull metastases and had severe weakness in her extremities that limited her mobility and daily activities. She was treated with 2 doses of Ra-dichloride (Xofigo, Ra) and had a dramatic improvement in pain control, mobility, and overall quality of life for 8 weeks, before passing away from pulmonary hemorrhage...
February 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/26222216/radiation-dose-and-hazard-assessment-of-potential-contamination-events-during-use-of-223ra-dichloride-in-radionuclide-therapy
#18
Michael G Stabin, Jeffry A Siegel
An analysis is presented of the possible dosimetric consequences of various potential contamination events involving 223Ra dichloride (Xofigo), the FDA-approved therapeutic agent used in the treatment of bone metastases in patients with castration-resistant prostate cancer. Three exposure scenarios are considered: inhalation dose to an individual due to the hypothetical inhalation of 219Rn and its progeny assumed to be released into the air from a liquid spill on the floor, external dose from direct photon exposure of an individual assigned to clean up a spill, and skin dose to an individual should the liquid material come into contact with their skin...
September 2015: Health Physics
https://www.readbyqxmd.com/read/26128591/mo-ab-201-03-the-alphabet-soup-of-regulatory-compliance-being-prepared-for-inspections
#19
L Kroger
UNLABELLED: The role of the Radiation Safety Officer at a medical facility can be complicated. The complexity of the position is based on the breadth of services provided at the institution and the nature of the radioactive materials license. Medical practices are constantly changing and the use of ionizing radiation continues to rise in this area. Some of the newer medical applications involving radiation have unique regulatory and safety issues that must be addressed. Oversight of the uses of radiation start at the local level (radiation safety officer, radiation safety committee) and are heavily impacted by outside agencies (i...
June 2015: Medical Physics
https://www.readbyqxmd.com/read/26128589/mo-ab-201-01-regulatory-compliance-and-safety-with-new-radiotherapies-spheres-and-ra-223
#20
L Phillips
UNLABELLED: The role of the Radiation Safety Officer at a medical facility can be complicated. The complexity of the position is based on the breadth of services provided at the institution and the nature of the radioactive materials license. Medical practices are constantly changing and the use of ionizing radiation continues to rise in this area. Some of the newer medical applications involving radiation have unique regulatory and safety issues that must be addressed. Oversight of the uses of radiation start at the local level (radiation safety officer, radiation safety committee) and are heavily impacted by outside agencies (i...
June 2015: Medical Physics
keyword
keyword
30034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"